| Overview |
| bs-11381R-Cy3 |
| A2LD1/GGACT Polyclonal Antibody, Cy3 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Dog, Horse, Rabbit |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human A2LD1 |
| 1-50/153 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 87769 |
| Q9BVM4 |
| Secreted, Extracellular matrix |
| A2LD1; Gamma-glutamylaminecyclotransferase; GGACT; AIG2-like domain-containing protein 1; Gamma-glutamylamine cyclotransferase |
| Contributes to degradation of proteins cross-linked by transglutaminases. Degrades the cross-link between a lysine and a glutamic acid residue from two proteins that have been cross-linked by transglutaminases. Catalyzes the formation of 5-oxoproline from L-gamma-glutamyl-L-epsilon-lysine. Inactive with L-gamma-glutamyl-alpha-amino acid substrates such as L-gamma-glutamyl-L-alpha-cysteine and L-gamma-glutamyl-L-alpha-alanine. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz